Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Aug 1;8(8):1137-1138.
doi: 10.1001/jamaoncol.2022.1623.

To Treat or Not to Treat Men With Low-risk or Intermediate-risk Prostate Cancer-Weighing the Evidence

Susan Halabi  1 , Bradley C Carthon  2 , Wm Kevin Kelly  3
Affiliations
Comment

To Treat or Not to Treat Men With Low-risk or Intermediate-risk Prostate Cancer-Weighing the Evidence

Susan Halabi et al. JAMA Oncol. .
No abstract available

PubMed Disclaimer

Comment on

References

    1. Shore N, Renzulli J, Fleshner N, Hollowell CM, Vourganti S, Silberstein J, Siddiqui J, Hairston J, Elsouda D, Russel D, Cooperberg MR, Tomlins SA: ENzalutamide Monotherapy Versus ACTive Surveillance in Patients With Low- or Intermediate-Risk Localized Prostate Cancer (ENACT): A Randomized Clinical Trial. JAMA Oncol, 2022 - PMC - PubMed
    1. Schaeffer E, Srinivas S, Antonarakis ES, Armstrong AJ, Cheng HH, D’Amico AV, Davis BJ, Dorff T, Farrington TA, GAo X, Gupta S, Guzzo T, Horwitz EM, Ippolito JE, Kuettel MR, Lang JM, McKenney J, McKay RR, Morgan T, Netto G, Penson DF, Plimack ER, Pow-Sang JM, Reiter R, Roach M, Robin T, Rosenfeld S, Shabsigh A, Teply BA, Tward J, Valicenti R: Prostate Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 2022
    1. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A, Wasielewska T, Welsbie D, Chen CD, Higano CS, Beer TM, Hung DT, Scher HI, Jung ME, Sawyers CL: Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324:787–90, 2009 - PMC - PubMed
    1. Cooley LF, Emeka AA, Meyers TJ, Cooper PR, Lin DW, Finelli A, Eastham JA, Logothetis CJ, Marks LS, Vesprini D, Goldenberg SL, Higano CS, Pavlovich CP, Chan JM, Morgan TM, Klein EA, Barocas DA, Loeb S, Helfand BT, Scholtens DM, Witte JS, Catalona WJ, Collaborators: Factors Associated with Time to Conversion from Active Surveillance to Treatment for Prostate Cancer in a Multi-Institutional Cohort. J Urol 206:1147–1156, 2021 - PMC - PubMed
    1. Fleshner NE, Lucia MS, Egerdie B, Aaron L, Eure G, Nandy I, Black L, Rittmaster RS: Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial. Lancet 379:1103–11, 2012 - PubMed

Substances